Vertex Pharmaceuticals
Genomics Plc Raises £25M, Collaborates With Vertex on Precision Medicine
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
Originally published Oct. 24.
Based on Phase III Data, Vertex Moving Quickly to File for Approval of Cystic Fibrosis Drug Combo
Premium
NEW YORK (GenomeWeb) — Vertex Pharmaceuticals this week released data from two Phase III studies of a combination of its cystic fibrosis drugs lumacaftor and Kalydeco (ivacaftor), showing that the studies have met their primary endpoints of statistically significant improvement in lung function a
Vertex Pharmaceuticals has been awarded
May 30, 2012
May 30, 2012
Jun 30, 2009
Feb 2, 2009